# Versa Vascular

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/versa-vascular

- Industry: Medical Devices & Equipment
- Headquarters: Santa Cruz, US
- Website: www.versavascular.com/
- Total disclosed funding: $42M
- Latest round: Series C (Aug 11, 2026)
- Investors on record: 5

## About

Versa Vascular specializes in tricuspid valve repair solutions, founded in 2020 in Santa Cruz, US. As of November 2025, the company is led by CEO David Hovda. In August 2026, Versa Vascular raised USD 15 million in series C funding from S3 Ventures and BioStar Capital.
Versa Vascular focuses on developing innovative solutions for tricuspid valve repair, targeting patients suffering from clinically significant tricuspid regurgitation. Their flagship product, the Versa Implant, is a minimally invasive device designed for placement within the right atrium, facilitating optimal blood flow while preserving native leaflet function. The Versa Implant is delivered through a sophisticated system that offers stable and precise placement, along with repositioning capabilities to improve procedural outcomes. Hospitals and healthcare providers in the US, where approximately 1.6 million individuals are affected by this condition, form the core customer base, as the company aims to provide effective treatment options that enhance patient quality of life.
Versa Vascular generates revenue primarily through collaborations with healthcare institutions and surgical centers that integrate their tricuspid valve repair solutions. Transactions are conducted on a B2B basis, where hospitals and clinics procure the Versa Implant along with its delivery systems for cardiac care. Pricing for these products is established through contractual agreements reflecting their specialized nature and clinical advantages. The firm's commitment to innovation aligns its offerings with the increasing demand for efficient cardiac treatments and minimally invasive surgical techniques.
The company plans to use the August 2026 funding to complete its first-in-human study outside the United States, initiate a U.S. Early Feasibility Study and continue product development and optimization of its AdapTR tricuspid valve repair technology.

## Funding rounds

- Series C, Aug 11, 2026, $15M — BioStar Capital, S3 Ventures
- Series C, Jul 29, 2025, $27M — BioStar Capital, S3 Ventures, View Ventures, Cadence Healthcare Ventures, Santa Cruz Ventures

## Investors

- BioStar Capital (https://capitalatlas.ai/funds/biostar-capital) — Series C
- S3 Ventures (https://capitalatlas.ai/funds/s3-ventures) — Series C
- View Ventures (https://capitalatlas.ai/funds/view-ventures) — Series C
- Cadence Healthcare Ventures — Series C
- Santa Cruz Ventures (https://capitalatlas.ai/funds/santa-cruz-ventures) — Series C